Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Galectin Therapeutics, Inc is a biotechnology business based in the US. Galectin Therapeutics shares (GALT) are listed on the NASDAQ and all prices are listed in US Dollars. Galectin Therapeutics employs 4 staff and has a market cap (total outstanding shares value) of USD$158.6 million.
Since the stock market crash in March caused by coronavirus, Galectin Therapeutics's share price has had significant positive movement.
Its last market close was USD$2.73, which is 6.23% up on its pre-crash value of USD$2.56 and 82.00% up on the lowest point reached during the March crash when the shares fell as low as USD$1.5.
If you had bought USD$1,000 worth of Galectin Therapeutics shares at the start of February 2020, those shares would have been worth USD$677.16 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,074.80.
|Latest market close||USD$2.73|
|52-week range||USD$1.5 - USD$4.5|
|50-day moving average||USD$2.7843|
|200-day moving average||USD$2.68|
|Wall St. target price||USD$12|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.418|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-23)||7.06%|
|1 month (2020-10-30)||7.48%|
|3 months (2020-08-28)||0.37%|
|6 months (2020-05-29)||-9.90%|
|1 year (2019-11-29)||-15.48%|
|2 years (2018-11-30)||-44.74%|
|3 years (2017-11-30)||15.68%|
|5 years (2015-11-30)||36.50%|
|Gross profit TTM||USD$0|
|Return on assets TTM||-23.5%|
|Return on equity TTM||-39.69%|
|Market capitalisation||USD$158.6 million|
TTM: trailing 12 months
There are currently 5.3 million Galectin Therapeutics shares held short by investors – that's known as Galectin Therapeutics's "short interest". This figure is 4.1% up from 5.1 million last month.
There are a few different ways that this level of interest in shorting Galectin Therapeutics shares can be evaluated.
Galectin Therapeutics's "short interest ratio" (SIR) is the quantity of Galectin Therapeutics shares currently shorted divided by the average quantity of Galectin Therapeutics shares traded daily (recently around 498698.21596244). Galectin Therapeutics's SIR currently stands at 10.65. In other words for every 100,000 Galectin Therapeutics shares traded daily on the market, roughly 10650 shares are currently held short.
However Galectin Therapeutics's short interest can also be evaluated against the total number of Galectin Therapeutics shares, or, against the total number of tradable Galectin Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Galectin Therapeutics's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Galectin Therapeutics shares in existence, roughly 90 shares are currently held short) or 0.1737% of the tradable shares (for every 100,000 tradable Galectin Therapeutics shares, roughly 174 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Galectin Therapeutics.
Find out more about how you can short Galectin Therapeutics stock.
We're not expecting Galectin Therapeutics to pay a dividend over the next 12 months.
Galectin Therapeutics's shares were split on a 1:6 basis on 23 March 2012. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Galectin Therapeutics shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Galectin Therapeutics shares which in turn could have impacted Galectin Therapeutics's share price.
Over the last 12 months, Galectin Therapeutics's shares have ranged in value from as little as $1.5 up to $4.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Galectin Therapeutics's is 2.3249. This would suggest that Galectin Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company's lead product candidate includes GR-MD-02 galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.